'On consolidated basis
Quarter ended March 2025 compared with Quarter ended March 2024.
Net sales (including other operating income) of Sun Pharmaceutical Industries has increased 8.14% to Rs 12958.84 crore. Operating profit margin has jumped from 25.33% to 28.68%, leading to 22.44% rise in operating profit to Rs 3,716.09 crore. Raw material cost as a % of total sales (net of stock adjustments) increased from 13.67% to 13.97%. Purchase of finished goods cost fell from 8.02% to 7.85%. Employee cost increased from 18.75% to 18.85%. Other expenses fell from 34.81% to 31.18%. Loss on forex transaction rose from 0.46% to 2.21%.
Other income rose 1.14% to Rs 612.87 crore. PBIDT rose 18.89% to Rs 4328.96 crore. Provision for interest fell 33.21% to Rs 49.14 crore. Loan funds declined from Rs 3,273.67 crore as of 31 March 2024 to Rs 2,362.19 crore...
Pleaselogin & subscribe to view the full report.
More Reports
|
|